

**ASX Release**

## **Cleansing Notice –Exercise of Options**

---

**26 May 2016, Sydney, Australia:** Viralytics Limited (ASX: VLA) (**Viralytics**) today issued 100,000 fully paid ordinary shares on the exercise of options with an exercise price of \$0.70. The options were issued to Mr Bryan Dulhunty's nominee following shareholder approval at the Company's 2011 Extraordinary General Meeting.

Viralytics has issued the shares without disclosure to investors under section 708A(5) Corporations Act 2001 (Cth) (**Corporations Act**).

**Details of the securities issued**

<b>Class of securities:</b>	Ordinary shares
<b>ASX Code of the securities:</b>	VLA
<b>Date of the issue or expected issue of the securities:</b>	26 May 2016
<b>Total number of securities issued or expected to be issued:</b>	100,000

As required by section 708A(6) of the Corporations Act, Viralytics advises:

- (a) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Viralytics has complied with:
  - (i) the provisions of chapter 2M of the Corporations Act as they apply to Viralytics; and
  - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

For and on behalf of the board of Viralytics.



Sarah Prince  
Company Secretary



### **About VIRALYTICS and CAVATAK™**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. Intratumoral, intravenous and intravesicular delivery routes are under investigation. Two combination studies with checkpoint inhibitors are underway in advanced melanoma patients, as well as a combination study of CAVATAK and KEYTRUDA in late-stage lung and bladder cancer patients.

Further details on our clinical and pre-clinical data can be found at:  
<http://www.viralytics.com/our-pipeline/clinical-trials/>

CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit [www.viralytics.com](http://www.viralytics.com).

### **Viralytics Investor/Media Contact:**

Dr Malcolm McColl  
Managing Director  
+61 2 9988 4000

Mr. Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333